Stifel initiated coverage on NewAmsterdam Pharma with a new price target
$NAMS
Biotechnology: Pharmaceutical Preparations
Health Care
Stifel initiated coverage of NewAmsterdam Pharma with a rating of Buy and set a new price target of $44.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/17/2025 | $42.00 | Buy | Citigroup |
| 6/10/2025 | $44.00 | Buy | Stifel |
| 6/4/2025 | $42.00 | Overweight | Cantor Fitzgerald |
| 12/30/2024 | $48.00 | Buy | H.C. Wainwright |
| 5/15/2024 | Buy | TD Cowen | |
| 3/14/2024 | $35.00 | Sector Outperform | Scotiabank |
| 1/18/2024 | $30.00 | Buy | Guggenheim |
| 1/16/2024 | $37.00 | Overweight | Piper Sandler |